30 Apr 2018 16:00
Premaitha Health plc
("Premaitha" or the "Company")
Notice of Trading Update
Manchester, UK - 30 April 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, is pleased to announce that Premaitha continued to demonstrate strong commercial progress in the year ended 31 March 2018 and the Company will issue a comprehensive trading update during May 2018.
For more information, please contact:
| |
Premaitha Health PLCDr Stephen Little, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@premaitha.com
| Tel: +44 (0)161 667 1053
|
Cairn Financial Advisers LLP (NOMAD)Liam Murray / James Caithie
| Tel: +44 (0)20 7213 0880 |
finnCap (Broker) Adrian Hargrave / Scott Mathieson (Corporate Finance) Andrew Burdis / Abigail Wayne (Corporate Broking)
| Tel: +44 (0)20 7220 0500 |
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock premaitha@vigocomms.com
| Tel: +44 (0)20 7830 9700
|
About Premaitha
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.
Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.